FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1901299664> ?p ?o ?g. }

• W1901299664 endingPage "3030" @default.
• W1901299664 startingPage "3025" @default.
• W1901299664 abstract "PURPOSE: To present the final analysis, with a median follow-up of 8 years, of the LNH87–2 randomized study, which compares consolidative sequential chemotherapy (ifosfamide plus etoposide, asparaginase, and cytarabine) with high-dose therapy (HDT) using cyclophosphamide, carmustine, and etoposide (CBV regimen) followed by stem-cell transplantation in patients with aggressive non-Hodgkin’s lymphoma in first complete remission after induction, focusing on high/intermediate- and high-risk patients identified by the age-adjusted international prognostic index. PATIENTS AND METHODS: Among the 916 eligible patients, 451 presented with two (n = 318) or three (n = 133) risk factors. After reaching complete remission to induction therapy, 236 of these higher risk patients were assessable for the consolidation phase, with 125 patients in the HDT arm and 111 in the sequential chemotherapy arm. RESULTS: Among these 451 higher risk patients, 277 (61%) achieved complete remission after induction treatment. In the population of 236 randomized patients, HDT was superior to sequential chemotherapy, with 8-year disease-free survival rates of 55% (95% confidence interval [CI], 46% to 64%) and 39% (95% CI, 30% to 48%), respectively (P = .02; relative risk, 1.56). The 8-year survival rate was significantly superior in the HDT arm (64%; 95% CI, 55% to 73%) compared with the sequential chemotherapy arm (49%; 95% CI, 39% to 59%) (P = .04; relative risk, 1.51). CONCLUSION: On the basis of the final analysis of this prospectively treated series of patients, retrospectively analyzed on the basis of the International Prognostic Index, we hypothesize that HDT benefits patients at higher risk who achieve complete remission after induction treatment." @default.
• W1901299664 created "2016-06-24" @default.
• W1901299664 creator A5003078312 @default.
• W1901299664 creator A5003105021 @default.
• W1901299664 creator A5006559442 @default.
• W1901299664 creator A5012900514 @default.
• W1901299664 creator A5018285104 @default.
• W1901299664 creator A5019680521 @default.
• W1901299664 creator A5022526324 @default.
• W1901299664 creator A5031041032 @default.
• W1901299664 creator A5035242323 @default.
• W1901299664 creator A5037247724 @default.
• W1901299664 creator A5050330963 @default.
• W1901299664 creator A5052452447 @default.
• W1901299664 creator A5056514957 @default.
• W1901299664 creator A5086354986 @default.
• W1901299664 creator A5086620890 @default.
• W1901299664 date "2000-08-16" @default.
• W1901299664 modified "2023-10-02" @default.
• W1901299664 title "Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study" @default.
• W1901299664 cites W1544519462 @default.
• W1901299664 cites W1818726713 @default.
• W1901299664 cites W1819949687 @default.
• W1901299664 cites W1846446924 @default.
• W1901299664 cites W1895128059 @default.
• W1901299664 cites W1896652710 @default.
• W1901299664 cites W1934485849 @default.
• W1901299664 cites W1997353354 @default.
• W1901299664 cites W2003999130 @default.
• W1901299664 cites W2142334769 @default.
• W1901299664 cites W2232762356 @default.
• W1901299664 cites W2274356580 @default.
• W1901299664 cites W2339293928 @default.
• W1901299664 cites W2415497810 @default.
• W1901299664 cites W321206321 @default.
• W1901299664 cites W4205736005 @default.
• W1901299664 cites W4293241248 @default.
• W1901299664 doi "https://doi.org/10.1200/jco.2000.18.16.3025" @default.
• W1901299664 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10944137" @default.
• W1901299664 hasPublicationYear "2000" @default.
• W1901299664 type Work @default.
• W1901299664 sameAs 1901299664 @default.
• W1901299664 citedByCount "410" @default.
• W1901299664 countsByYear W19012996642012 @default.
• W1901299664 countsByYear W19012996642013 @default.
• W1901299664 countsByYear W19012996642014 @default.
• W1901299664 countsByYear W19012996642015 @default.
• W1901299664 countsByYear W19012996642016 @default.
• W1901299664 countsByYear W19012996642017 @default.
• W1901299664 countsByYear W19012996642018 @default.
• W1901299664 countsByYear W19012996642019 @default.
• W1901299664 countsByYear W19012996642020 @default.
• W1901299664 countsByYear W19012996642021 @default.
• W1901299664 countsByYear W19012996642022 @default.
• W1901299664 countsByYear W19012996642023 @default.
• W1901299664 crossrefType "journal-article" @default.
• W1901299664 hasAuthorship W1901299664A5003078312 @default.
• W1901299664 hasAuthorship W1901299664A5003105021 @default.
• W1901299664 hasAuthorship W1901299664A5006559442 @default.
• W1901299664 hasAuthorship W1901299664A5012900514 @default.
• W1901299664 hasAuthorship W1901299664A5018285104 @default.
• W1901299664 hasAuthorship W1901299664A5019680521 @default.
• W1901299664 hasAuthorship W1901299664A5022526324 @default.
• W1901299664 hasAuthorship W1901299664A5031041032 @default.
• W1901299664 hasAuthorship W1901299664A5035242323 @default.
• W1901299664 hasAuthorship W1901299664A5037247724 @default.
• W1901299664 hasAuthorship W1901299664A5050330963 @default.
• W1901299664 hasAuthorship W1901299664A5052452447 @default.
• W1901299664 hasAuthorship W1901299664A5056514957 @default.
• W1901299664 hasAuthorship W1901299664A5086354986 @default.
• W1901299664 hasAuthorship W1901299664A5086620890 @default.
• W1901299664 hasConcept C126322002 @default.
• W1901299664 hasConcept C141071460 @default.
• W1901299664 hasConcept C2776694085 @default.
• W1901299664 hasConcept C2776755627 @default.
• W1901299664 hasConcept C2777506904 @default.
• W1901299664 hasConcept C2778041864 @default.
• W1901299664 hasConcept C2778119113 @default.
• W1901299664 hasConcept C2778476033 @default.
• W1901299664 hasConcept C2780147359 @default.
• W1901299664 hasConcept C2781413609 @default.
• W1901299664 hasConcept C2908647359 @default.
• W1901299664 hasConcept C2911091166 @default.
• W1901299664 hasConcept C71924100 @default.
• W1901299664 hasConcept C99454951 @default.
• W1901299664 hasConceptScore W1901299664C126322002 @default.
• W1901299664 hasConceptScore W1901299664C141071460 @default.
• W1901299664 hasConceptScore W1901299664C2776694085 @default.
• W1901299664 hasConceptScore W1901299664C2776755627 @default.
• W1901299664 hasConceptScore W1901299664C2777506904 @default.
• W1901299664 hasConceptScore W1901299664C2778041864 @default.
• W1901299664 hasConceptScore W1901299664C2778119113 @default.
• W1901299664 hasConceptScore W1901299664C2778476033 @default.
• W1901299664 hasConceptScore W1901299664C2780147359 @default.
• W1901299664 hasConceptScore W1901299664C2781413609 @default.
• W1901299664 hasConceptScore W1901299664C2908647359 @default.
• W1901299664 hasConceptScore W1901299664C2911091166 @default.
• W1901299664 hasConceptScore W1901299664C71924100 @default.

• next